Citation: Wj. Gullick et R. Srinivasan, The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer, BREAST CANC, 52(1-3), 1998, pp. 43-53
Authors:
Stephens, RW
Brunner, N
Janicke, F
Schmitt, M
Citation: Rw. Stephens et al., The urokinase plasminogen activator system as a target for prognostic studies in breast cancer, BREAST CANC, 52(1-3), 1998, pp. 99-111
Authors:
Heimann, R
Ferguson, D
Gray, S
Hellman, S
Citation: R. Heimann et al., Assessment of intratumoral vascularization (angiogenesis) in breast cancerprognosis, BREAST CANC, 52(1-3), 1998, pp. 147-158
Citation: I. Jatoi, Timing of surgery for primary breast cancer with regard to the menstrual phase and prognosis, BREAST CANC, 52(1-3), 1998, pp. 217-225
Authors:
Hilsenbeck, SG
Ravdin, PM
de Moor, CA
Chamness, GC
Osborne, CK
Clark, GM
Citation: Sg. Hilsenbeck et al., Time-dependence of hazard ratios for prognostic factors in primary breast cancer, BREAST CANC, 52(1-3), 1998, pp. 227-237
Citation: V. Stearns et al., Circulating tumor markers in breast cancer: Accepted utilities and novel prospects, BREAST CANC, 52(1-3), 1998, pp. 239-259
Citation: Ic. Henderson et Aj. Patek, The relationship between prognostic and predictive factors in the management of breast cancer, BREAST CANC, 52(1-3), 1998, pp. 261-288
Citation: Dg. Altman et Gh. Lyman, Methodological challenges in the evaluation of prognostic factors in breast cancer, BREAST CANC, 52(1-3), 1998, pp. 289-303
Citation: Df. Hayes et al., Assessing the clinical impact of prognostic factors: When is "statistically significant" clinically useful?, BREAST CANC, 52(1-3), 1998, pp. 305-319